Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
RESEARCH TOOLSreports
Holding ACAD?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.22Last Year’s EPS
$0.28Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 6.84%
|Next Earnings Date:Mar 03, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, particularly for Daybue and NUPLAZID, and promising pipeline developments. However, challenges with patient discontinuation, increased expenses, and delayed impact from marketing campaigns were noted. The overall sentiment reflects a positive outlook with some operational challenges.Company Guidance
During the Q3 2024 earnings call for Acadia Pharmaceuticals, the guidance provided highlighted several key metrics and strategic focuses. Acadia's financial outlook for 2024 includes narrowing the net sales guidance for Daybue to a range of $340 million to $350 million and for NUPLAZID to $600 million to $610 million. The company also revised its NUPLAZID gross-to-net guidance to 26%-27%. Acadia anticipates a cash balance of $600 million to $640 million, excluding the anticipated proceeds from the sale of a priority review voucher, expected to close in Q4 for $150 million, with one-third of the net proceeds owed to Neuren. The company reported $250.4 million in net sales for the quarter, marking an 18% year-over-year increase, and a growing cash position now at $565 million. Acadia remains focused on executing its late-stage clinical trials and continues to explore business development opportunities to drive future growth.Strong Revenue Growth
ACADIA reported a total net sales increase of 18% from the third quarter of last year, with Daybue and NUPLAZID contributing significantly to this growth.
Daybue Sales Performance
Daybue net product sales were $91.2 million in Q3, up 36% year-over-year and 8% sequentially. This indicates solid market penetration and patient retention.
NUPLAZID Sales Achievement
NUPLAZID achieved net product sales of $159.2 million, marking the highest ever quarterly sales for the brand with a year-over-year growth of 10%.
Pipeline Developments
The company has promising late-stage assets in Prader-Willi syndrome and Alzheimer's disease psychosis, with ongoing efforts in global expansion including recent approval from Health Canada for Daybue.
Financial Strength
ACADIA reported a cash balance increase to $565.3 million, reflecting strong operational performance and cash flow generation.
---
ACAD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ACAD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $15.79 | $17.20 | +8.93% |
| Aug 06, 2024 | $18.85 | $15.17 | -19.52% |
| May 08, 2024 | $17.13 | $15.21 | -11.21% |
| Feb 27, 2024 | $26.36 | $23.74 | -9.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ACADIA Pharmaceuticals (ACAD) report earnings?
ACADIA Pharmaceuticals (ACAD) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is ACADIA Pharmaceuticals (ACAD) earnings time?
ACADIA Pharmaceuticals (ACAD) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACAD EPS forecast?
ACAD EPS forecast for the fiscal quarter 2024 (Q4) is $0.22.
---